Global Blockbuster Drugs Market

Blockbuster Drugs Comprehensive Study by Type (Generic Drug, Brand Name Drug), Application (Oncology, Immunology, Autoimmune Diseases, Cardiovascular Diseases, Other), Route of Administration (Oral, Injectable), Distribution Channel (Online, Offline) Players and Region - Global Market Outlook to 2030

Blockbuster Drugs Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Blockbuster Drugs
Over the past few years blockbuster to be born supposed to develop aggressive marketing with rising sales volumes in order to secure monopolistic rents offered by patents rapidly. Blockbuster drugs are defined as the drugs that generate at least USD1 billion in revenue a year for the pharmaceutical companies that produce them Blockbuster drugs are used to treat various ac medical problems. For instance, the medications used to treat diabetes, cholesterol, high blood pressure, and cancer. Part of the success of these drugs stems from the fact that they're needed over a long period of time, and that they play a key role in helping doctors manage their patients' conditions. For this reason, the pharma companies are aiming to develop a diverse and successful range of products instead of depending on one or two blockbuster drugs to keep themselves profitable is booming the demand for blockbuster drugs in the market

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Blockbuster Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Roche (Switzerland), Bristol-Myers Squibb(United States), Pfizer(United States), Eli Lilly and Company(United States), Merck & Co. (United States), Johnson & Johnson (United States), AstraZeneca (United Kingdom), Celgene (United States), Novartis (Switzerland) and Amgen (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Johnson & Johnson (United States) and Bristol Myers Squibb (United States).

Segmentation Overview
AMA Research has segmented the market of Global Blockbuster Drugs market by Type (Generic Drug and Brand Name Drug), Application (Oncology, Immunology, Autoimmune Diseases, Cardiovascular Diseases and Other) and Region.



On the basis of geography, the market of Blockbuster Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Blockbuster Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Online will boost the Blockbuster Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
The structural trend of increasing pharmaceuticals spending in richer countries and the rising cost of clinical trials still push pharmaceutical groups to focus on the most profitable therapeutic areas cholesterol, oncology, central nervous system, etc

Market Growth Drivers:
Fastest growing pharma companies are generic and have growth is one of the key driving factors of growth of the market, Niche pharma companies are also adopting a similar approach and High investing in R&D and commercialization of high-value blockbuster drugs

Challenges:
Price fluctuations, expiry of patents

Restraints:
Stringent laws for the patent and Poor presence in growing Europe and Asia

Opportunities:
Increasing research and development (R&D) of new drug and Pharma companies are adopting aggressive marketing strategies to bank on early sales of newly launched products. This gives their product a larger lifetime before the expiry of patents




Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Blockbuster Drugs Manufacturer, Government Regulatory and Research Organizations and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Generic Drug
  • Brand Name Drug
By Application
  • Oncology
  • Immunology
  • Autoimmune Diseases
  • Cardiovascular Diseases
  • Other
By Route of Administration
  • Oral
  • Injectable

By Distribution Channel
  • Online
  • Offline

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Fastest growing pharma companies are generic and have growth is one of the key driving factors of growth of the market
      • 3.2.2. Niche pharma companies are also adopting a similar approach
      • 3.2.3. High investing in R&D and commercialization of high-value blockbuster drugs
    • 3.3. Market Challenges
      • 3.3.1. Price fluctuations, expiry of patents
    • 3.4. Market Trends
      • 3.4.1. The structural trend of increasing pharmaceuticals spending in richer countries and the rising cost of clinical trials still push pharmaceutical groups to focus on the most profitable therapeutic areas cholesterol, oncology, central nervous system, etc
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Blockbuster Drugs, by Type, Application, Route of Administration, Distribution Channel and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Blockbuster Drugs (Value)
      • 5.2.1. Global Blockbuster Drugs by: Type (Value)
        • 5.2.1.1. Generic Drug
        • 5.2.1.2. Brand Name Drug
      • 5.2.2. Global Blockbuster Drugs by: Application (Value)
        • 5.2.2.1. Oncology
        • 5.2.2.2. Immunology
        • 5.2.2.3. Autoimmune Diseases
        • 5.2.2.4. Cardiovascular Diseases
        • 5.2.2.5. Other
      • 5.2.3. Global Blockbuster Drugs by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Injectable
      • 5.2.4. Global Blockbuster Drugs by: Distribution Channel (Value)
        • 5.2.4.1. Online
        • 5.2.4.2. Offline
      • 5.2.5. Global Blockbuster Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Blockbuster Drugs (Volume)
      • 5.3.1. Global Blockbuster Drugs by: Type (Volume)
        • 5.3.1.1. Generic Drug
        • 5.3.1.2. Brand Name Drug
      • 5.3.2. Global Blockbuster Drugs by: Application (Volume)
        • 5.3.2.1. Oncology
        • 5.3.2.2. Immunology
        • 5.3.2.3. Autoimmune Diseases
        • 5.3.2.4. Cardiovascular Diseases
        • 5.3.2.5. Other
      • 5.3.3. Global Blockbuster Drugs by: Route of Administration (Volume)
        • 5.3.3.1. Oral
        • 5.3.3.2. Injectable
      • 5.3.4. Global Blockbuster Drugs by: Distribution Channel (Volume)
        • 5.3.4.1. Online
        • 5.3.4.2. Offline
      • 5.3.5. Global Blockbuster Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Blockbuster Drugs (Price)
      • 5.4.1. Global Blockbuster Drugs by: Type (Price)
  • 6. Blockbuster Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bristol-Myers Squibb(United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer(United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lilly and Company(United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck & Co. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AstraZeneca (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Celgene (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Amgen (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Blockbuster Drugs Sale, by Type, Application, Route of Administration, Distribution Channel and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Blockbuster Drugs (Value)
      • 7.2.1. Global Blockbuster Drugs by: Type (Value)
        • 7.2.1.1. Generic Drug
        • 7.2.1.2. Brand Name Drug
      • 7.2.2. Global Blockbuster Drugs by: Application (Value)
        • 7.2.2.1. Oncology
        • 7.2.2.2. Immunology
        • 7.2.2.3. Autoimmune Diseases
        • 7.2.2.4. Cardiovascular Diseases
        • 7.2.2.5. Other
      • 7.2.3. Global Blockbuster Drugs by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Injectable
      • 7.2.4. Global Blockbuster Drugs by: Distribution Channel (Value)
        • 7.2.4.1. Online
        • 7.2.4.2. Offline
      • 7.2.5. Global Blockbuster Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Blockbuster Drugs (Volume)
      • 7.3.1. Global Blockbuster Drugs by: Type (Volume)
        • 7.3.1.1. Generic Drug
        • 7.3.1.2. Brand Name Drug
      • 7.3.2. Global Blockbuster Drugs by: Application (Volume)
        • 7.3.2.1. Oncology
        • 7.3.2.2. Immunology
        • 7.3.2.3. Autoimmune Diseases
        • 7.3.2.4. Cardiovascular Diseases
        • 7.3.2.5. Other
      • 7.3.3. Global Blockbuster Drugs by: Route of Administration (Volume)
        • 7.3.3.1. Oral
        • 7.3.3.2. Injectable
      • 7.3.4. Global Blockbuster Drugs by: Distribution Channel (Volume)
        • 7.3.4.1. Online
        • 7.3.4.2. Offline
      • 7.3.5. Global Blockbuster Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Blockbuster Drugs (Price)
      • 7.4.1. Global Blockbuster Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Blockbuster Drugs: by Type(USD Million)
  • Table 2. Blockbuster Drugs Generic Drug , by Region USD Million (2018-2023)
  • Table 3. Blockbuster Drugs Brand Name Drug , by Region USD Million (2018-2023)
  • Table 4. Blockbuster Drugs: by Application(USD Million)
  • Table 5. Blockbuster Drugs Oncology , by Region USD Million (2018-2023)
  • Table 6. Blockbuster Drugs Immunology , by Region USD Million (2018-2023)
  • Table 7. Blockbuster Drugs Autoimmune Diseases , by Region USD Million (2018-2023)
  • Table 8. Blockbuster Drugs Cardiovascular Diseases , by Region USD Million (2018-2023)
  • Table 9. Blockbuster Drugs Other , by Region USD Million (2018-2023)
  • Table 10. Blockbuster Drugs: by Route of Administration(USD Million)
  • Table 11. Blockbuster Drugs Oral , by Region USD Million (2018-2023)
  • Table 12. Blockbuster Drugs Injectable , by Region USD Million (2018-2023)
  • Table 13. Blockbuster Drugs: by Distribution Channel(USD Million)
  • Table 14. Blockbuster Drugs Online , by Region USD Million (2018-2023)
  • Table 15. Blockbuster Drugs Offline , by Region USD Million (2018-2023)
  • Table 16. South America Blockbuster Drugs, by Country USD Million (2018-2023)
  • Table 17. South America Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 18. South America Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 19. South America Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 20. South America Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 21. Brazil Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 22. Brazil Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 23. Brazil Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 24. Brazil Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 25. Argentina Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 26. Argentina Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 27. Argentina Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 28. Argentina Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 29. Rest of South America Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 30. Rest of South America Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 31. Rest of South America Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 32. Rest of South America Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 33. Asia Pacific Blockbuster Drugs, by Country USD Million (2018-2023)
  • Table 34. Asia Pacific Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 35. Asia Pacific Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 36. Asia Pacific Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 37. Asia Pacific Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 38. China Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 39. China Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 40. China Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 41. China Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 42. Japan Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 43. Japan Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 44. Japan Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 45. Japan Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 46. India Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 47. India Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 48. India Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 49. India Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 50. South Korea Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 51. South Korea Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 52. South Korea Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 53. South Korea Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 54. Taiwan Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 55. Taiwan Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 56. Taiwan Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 57. Taiwan Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 58. Australia Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 59. Australia Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 60. Australia Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 61. Australia Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 66. Europe Blockbuster Drugs, by Country USD Million (2018-2023)
  • Table 67. Europe Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 68. Europe Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 69. Europe Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 70. Europe Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 71. Germany Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 72. Germany Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 73. Germany Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 74. Germany Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 75. France Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 76. France Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 77. France Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 78. France Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 79. Italy Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 80. Italy Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 81. Italy Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 82. Italy Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 83. United Kingdom Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 84. United Kingdom Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 85. United Kingdom Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 86. United Kingdom Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 87. Netherlands Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 88. Netherlands Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 89. Netherlands Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 90. Netherlands Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 91. Rest of Europe Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 92. Rest of Europe Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 93. Rest of Europe Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 94. Rest of Europe Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 95. MEA Blockbuster Drugs, by Country USD Million (2018-2023)
  • Table 96. MEA Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 97. MEA Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 98. MEA Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 99. MEA Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 100. Middle East Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 101. Middle East Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 102. Middle East Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 103. Middle East Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 104. Africa Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 105. Africa Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 106. Africa Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 107. Africa Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 108. North America Blockbuster Drugs, by Country USD Million (2018-2023)
  • Table 109. North America Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 110. North America Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 111. North America Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 112. North America Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 113. United States Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 114. United States Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 115. United States Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 116. United States Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 117. Canada Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 118. Canada Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 119. Canada Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 120. Canada Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 121. Mexico Blockbuster Drugs, by Type USD Million (2018-2023)
  • Table 122. Mexico Blockbuster Drugs, by Application USD Million (2018-2023)
  • Table 123. Mexico Blockbuster Drugs, by Route of Administration USD Million (2018-2023)
  • Table 124. Mexico Blockbuster Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 125. Blockbuster Drugs Sales: by Type(K Tons)
  • Table 126. Blockbuster Drugs Sales Generic Drug , by Region K Tons (2018-2023)
  • Table 127. Blockbuster Drugs Sales Brand Name Drug , by Region K Tons (2018-2023)
  • Table 128. Blockbuster Drugs Sales: by Application(K Tons)
  • Table 129. Blockbuster Drugs Sales Oncology , by Region K Tons (2018-2023)
  • Table 130. Blockbuster Drugs Sales Immunology , by Region K Tons (2018-2023)
  • Table 131. Blockbuster Drugs Sales Autoimmune Diseases , by Region K Tons (2018-2023)
  • Table 132. Blockbuster Drugs Sales Cardiovascular Diseases , by Region K Tons (2018-2023)
  • Table 133. Blockbuster Drugs Sales Other , by Region K Tons (2018-2023)
  • Table 134. Blockbuster Drugs Sales: by Route of Administration(K Tons)
  • Table 135. Blockbuster Drugs Sales Oral , by Region K Tons (2018-2023)
  • Table 136. Blockbuster Drugs Sales Injectable , by Region K Tons (2018-2023)
  • Table 137. Blockbuster Drugs Sales: by Distribution Channel(K Tons)
  • Table 138. Blockbuster Drugs Sales Online , by Region K Tons (2018-2023)
  • Table 139. Blockbuster Drugs Sales Offline , by Region K Tons (2018-2023)
  • Table 140. South America Blockbuster Drugs Sales, by Country K Tons (2018-2023)
  • Table 141. South America Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 142. South America Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 143. South America Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 144. South America Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 145. Brazil Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 146. Brazil Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 147. Brazil Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 148. Brazil Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 149. Argentina Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 150. Argentina Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 151. Argentina Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 152. Argentina Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 153. Rest of South America Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 154. Rest of South America Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 155. Rest of South America Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 156. Rest of South America Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 157. Asia Pacific Blockbuster Drugs Sales, by Country K Tons (2018-2023)
  • Table 158. Asia Pacific Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 159. Asia Pacific Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 160. Asia Pacific Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 161. Asia Pacific Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 162. China Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 163. China Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 164. China Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 165. China Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 166. Japan Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 167. Japan Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 168. Japan Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 169. Japan Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 170. India Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 171. India Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 172. India Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 173. India Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 174. South Korea Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 175. South Korea Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 176. South Korea Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 177. South Korea Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 178. Taiwan Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 179. Taiwan Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 180. Taiwan Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 181. Taiwan Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 182. Australia Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 183. Australia Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 184. Australia Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 185. Australia Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 186. Rest of Asia-Pacific Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 187. Rest of Asia-Pacific Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 188. Rest of Asia-Pacific Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 189. Rest of Asia-Pacific Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 190. Europe Blockbuster Drugs Sales, by Country K Tons (2018-2023)
  • Table 191. Europe Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 192. Europe Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 193. Europe Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 194. Europe Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 195. Germany Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 196. Germany Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 197. Germany Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 198. Germany Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 199. France Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 200. France Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 201. France Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 202. France Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 203. Italy Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 204. Italy Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 205. Italy Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 206. Italy Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 207. United Kingdom Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 208. United Kingdom Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 209. United Kingdom Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 210. United Kingdom Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 211. Netherlands Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 212. Netherlands Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 213. Netherlands Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 214. Netherlands Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 215. Rest of Europe Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 216. Rest of Europe Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 217. Rest of Europe Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 218. Rest of Europe Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 219. MEA Blockbuster Drugs Sales, by Country K Tons (2018-2023)
  • Table 220. MEA Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 221. MEA Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 222. MEA Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 223. MEA Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 224. Middle East Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 225. Middle East Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 226. Middle East Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 227. Middle East Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 228. Africa Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 229. Africa Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 230. Africa Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 231. Africa Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 232. North America Blockbuster Drugs Sales, by Country K Tons (2018-2023)
  • Table 233. North America Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 234. North America Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 235. North America Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 236. North America Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 237. United States Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 238. United States Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 239. United States Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 240. United States Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 241. Canada Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 242. Canada Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 243. Canada Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 244. Canada Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 245. Mexico Blockbuster Drugs Sales, by Type K Tons (2018-2023)
  • Table 246. Mexico Blockbuster Drugs Sales, by Application K Tons (2018-2023)
  • Table 247. Mexico Blockbuster Drugs Sales, by Route of Administration K Tons (2018-2023)
  • Table 248. Mexico Blockbuster Drugs Sales, by Distribution Channel K Tons (2018-2023)
  • Table 249. Blockbuster Drugs: by Type(USD/Units)
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Blockbuster Drugs: by Type(USD Million)
  • Table 261. Blockbuster Drugs Generic Drug , by Region USD Million (2025-2030)
  • Table 262. Blockbuster Drugs Brand Name Drug , by Region USD Million (2025-2030)
  • Table 263. Blockbuster Drugs: by Application(USD Million)
  • Table 264. Blockbuster Drugs Oncology , by Region USD Million (2025-2030)
  • Table 265. Blockbuster Drugs Immunology , by Region USD Million (2025-2030)
  • Table 266. Blockbuster Drugs Autoimmune Diseases , by Region USD Million (2025-2030)
  • Table 267. Blockbuster Drugs Cardiovascular Diseases , by Region USD Million (2025-2030)
  • Table 268. Blockbuster Drugs Other , by Region USD Million (2025-2030)
  • Table 269. Blockbuster Drugs: by Route of Administration(USD Million)
  • Table 270. Blockbuster Drugs Oral , by Region USD Million (2025-2030)
  • Table 271. Blockbuster Drugs Injectable , by Region USD Million (2025-2030)
  • Table 272. Blockbuster Drugs: by Distribution Channel(USD Million)
  • Table 273. Blockbuster Drugs Online , by Region USD Million (2025-2030)
  • Table 274. Blockbuster Drugs Offline , by Region USD Million (2025-2030)
  • Table 275. South America Blockbuster Drugs, by Country USD Million (2025-2030)
  • Table 276. South America Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 277. South America Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 278. South America Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 279. South America Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 280. Brazil Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 281. Brazil Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 282. Brazil Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 283. Brazil Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 284. Argentina Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 285. Argentina Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 286. Argentina Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 287. Argentina Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 288. Rest of South America Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 289. Rest of South America Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 290. Rest of South America Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 291. Rest of South America Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 292. Asia Pacific Blockbuster Drugs, by Country USD Million (2025-2030)
  • Table 293. Asia Pacific Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 294. Asia Pacific Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 295. Asia Pacific Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 296. Asia Pacific Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 297. China Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 298. China Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 299. China Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 300. China Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 301. Japan Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 302. Japan Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 303. Japan Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 304. Japan Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 305. India Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 306. India Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 307. India Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 308. India Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 309. South Korea Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 310. South Korea Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 311. South Korea Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 312. South Korea Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 313. Taiwan Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 314. Taiwan Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 315. Taiwan Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 316. Taiwan Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 317. Australia Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 318. Australia Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 319. Australia Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 320. Australia Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 321. Rest of Asia-Pacific Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 322. Rest of Asia-Pacific Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 323. Rest of Asia-Pacific Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 324. Rest of Asia-Pacific Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 325. Europe Blockbuster Drugs, by Country USD Million (2025-2030)
  • Table 326. Europe Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 327. Europe Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 328. Europe Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 329. Europe Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 330. Germany Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 331. Germany Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 332. Germany Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 333. Germany Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 334. France Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 335. France Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 336. France Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 337. France Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 338. Italy Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 339. Italy Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 340. Italy Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 341. Italy Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 342. United Kingdom Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 343. United Kingdom Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 344. United Kingdom Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 345. United Kingdom Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 346. Netherlands Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 347. Netherlands Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 348. Netherlands Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 349. Netherlands Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 350. Rest of Europe Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 351. Rest of Europe Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 352. Rest of Europe Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 353. Rest of Europe Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 354. MEA Blockbuster Drugs, by Country USD Million (2025-2030)
  • Table 355. MEA Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 356. MEA Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 357. MEA Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 358. MEA Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 359. Middle East Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 360. Middle East Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 361. Middle East Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 362. Middle East Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 363. Africa Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 364. Africa Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 365. Africa Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 366. Africa Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 367. North America Blockbuster Drugs, by Country USD Million (2025-2030)
  • Table 368. North America Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 369. North America Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 370. North America Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 371. North America Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 372. United States Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 373. United States Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 374. United States Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 375. United States Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 376. Canada Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 377. Canada Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 378. Canada Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 379. Canada Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 380. Mexico Blockbuster Drugs, by Type USD Million (2025-2030)
  • Table 381. Mexico Blockbuster Drugs, by Application USD Million (2025-2030)
  • Table 382. Mexico Blockbuster Drugs, by Route of Administration USD Million (2025-2030)
  • Table 383. Mexico Blockbuster Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 384. Blockbuster Drugs Sales: by Type(K Tons)
  • Table 385. Blockbuster Drugs Sales Generic Drug , by Region K Tons (2025-2030)
  • Table 386. Blockbuster Drugs Sales Brand Name Drug , by Region K Tons (2025-2030)
  • Table 387. Blockbuster Drugs Sales: by Application(K Tons)
  • Table 388. Blockbuster Drugs Sales Oncology , by Region K Tons (2025-2030)
  • Table 389. Blockbuster Drugs Sales Immunology , by Region K Tons (2025-2030)
  • Table 390. Blockbuster Drugs Sales Autoimmune Diseases , by Region K Tons (2025-2030)
  • Table 391. Blockbuster Drugs Sales Cardiovascular Diseases , by Region K Tons (2025-2030)
  • Table 392. Blockbuster Drugs Sales Other , by Region K Tons (2025-2030)
  • Table 393. Blockbuster Drugs Sales: by Route of Administration(K Tons)
  • Table 394. Blockbuster Drugs Sales Oral , by Region K Tons (2025-2030)
  • Table 395. Blockbuster Drugs Sales Injectable , by Region K Tons (2025-2030)
  • Table 396. Blockbuster Drugs Sales: by Distribution Channel(K Tons)
  • Table 397. Blockbuster Drugs Sales Online , by Region K Tons (2025-2030)
  • Table 398. Blockbuster Drugs Sales Offline , by Region K Tons (2025-2030)
  • Table 399. South America Blockbuster Drugs Sales, by Country K Tons (2025-2030)
  • Table 400. South America Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 401. South America Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 402. South America Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 403. South America Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 404. Brazil Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 405. Brazil Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 406. Brazil Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 407. Brazil Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 408. Argentina Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 409. Argentina Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 410. Argentina Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 411. Argentina Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 412. Rest of South America Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 413. Rest of South America Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 414. Rest of South America Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 415. Rest of South America Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 416. Asia Pacific Blockbuster Drugs Sales, by Country K Tons (2025-2030)
  • Table 417. Asia Pacific Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 418. Asia Pacific Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 419. Asia Pacific Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 420. Asia Pacific Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 421. China Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 422. China Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 423. China Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 424. China Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 425. Japan Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 426. Japan Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 427. Japan Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 428. Japan Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 429. India Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 430. India Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 431. India Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 432. India Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 433. South Korea Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 434. South Korea Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 435. South Korea Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 436. South Korea Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 437. Taiwan Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 438. Taiwan Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 439. Taiwan Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 440. Taiwan Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 441. Australia Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 442. Australia Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 443. Australia Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 444. Australia Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 445. Rest of Asia-Pacific Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 446. Rest of Asia-Pacific Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 447. Rest of Asia-Pacific Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 448. Rest of Asia-Pacific Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 449. Europe Blockbuster Drugs Sales, by Country K Tons (2025-2030)
  • Table 450. Europe Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 451. Europe Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 452. Europe Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 453. Europe Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 454. Germany Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 455. Germany Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 456. Germany Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 457. Germany Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 458. France Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 459. France Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 460. France Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 461. France Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 462. Italy Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 463. Italy Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 464. Italy Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 465. Italy Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 466. United Kingdom Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 467. United Kingdom Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 468. United Kingdom Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 469. United Kingdom Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 470. Netherlands Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 471. Netherlands Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 472. Netherlands Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 473. Netherlands Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 474. Rest of Europe Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 475. Rest of Europe Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 476. Rest of Europe Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 477. Rest of Europe Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 478. MEA Blockbuster Drugs Sales, by Country K Tons (2025-2030)
  • Table 479. MEA Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 480. MEA Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 481. MEA Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 482. MEA Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 483. Middle East Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 484. Middle East Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 485. Middle East Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 486. Middle East Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 487. Africa Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 488. Africa Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 489. Africa Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 490. Africa Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 491. North America Blockbuster Drugs Sales, by Country K Tons (2025-2030)
  • Table 492. North America Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 493. North America Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 494. North America Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 495. North America Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 496. United States Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 497. United States Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 498. United States Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 499. United States Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 500. Canada Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 501. Canada Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 502. Canada Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 503. Canada Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 504. Mexico Blockbuster Drugs Sales, by Type K Tons (2025-2030)
  • Table 505. Mexico Blockbuster Drugs Sales, by Application K Tons (2025-2030)
  • Table 506. Mexico Blockbuster Drugs Sales, by Route of Administration K Tons (2025-2030)
  • Table 507. Mexico Blockbuster Drugs Sales, by Distribution Channel K Tons (2025-2030)
  • Table 508. Blockbuster Drugs: by Type(USD/Units)
  • Table 509. Research Programs/Design for This Report
  • Table 510. Key Data Information from Secondary Sources
  • Table 511. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Blockbuster Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Blockbuster Drugs: by Application USD Million (2018-2023)
  • Figure 6. Global Blockbuster Drugs: by Route of Administration USD Million (2018-2023)
  • Figure 7. Global Blockbuster Drugs: by Distribution Channel USD Million (2018-2023)
  • Figure 8. South America Blockbuster Drugs Share (%), by Country
  • Figure 9. Asia Pacific Blockbuster Drugs Share (%), by Country
  • Figure 10. Europe Blockbuster Drugs Share (%), by Country
  • Figure 11. MEA Blockbuster Drugs Share (%), by Country
  • Figure 12. North America Blockbuster Drugs Share (%), by Country
  • Figure 13. Global Blockbuster Drugs: by Type K Tons (2018-2023)
  • Figure 14. Global Blockbuster Drugs: by Application K Tons (2018-2023)
  • Figure 15. Global Blockbuster Drugs: by Route of Administration K Tons (2018-2023)
  • Figure 16. Global Blockbuster Drugs: by Distribution Channel K Tons (2018-2023)
  • Figure 17. South America Blockbuster Drugs Share (%), by Country
  • Figure 18. Asia Pacific Blockbuster Drugs Share (%), by Country
  • Figure 19. Europe Blockbuster Drugs Share (%), by Country
  • Figure 20. MEA Blockbuster Drugs Share (%), by Country
  • Figure 21. North America Blockbuster Drugs Share (%), by Country
  • Figure 22. Global Blockbuster Drugs: by Type USD/Units (2018-2023)
  • Figure 23. Global Blockbuster Drugs share by Players 2023 (%)
  • Figure 24. Global Blockbuster Drugs share by Players (Top 3) 2023(%)
  • Figure 25. Global Blockbuster Drugs share by Players (Top 5) 2023(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Roche (Switzerland) Revenue: by Geography 2023
  • Figure 29. Bristol-Myers Squibb(United States) Revenue, Net Income and Gross profit
  • Figure 30. Bristol-Myers Squibb(United States) Revenue: by Geography 2023
  • Figure 31. Pfizer(United States) Revenue, Net Income and Gross profit
  • Figure 32. Pfizer(United States) Revenue: by Geography 2023
  • Figure 33. Eli Lilly and Company(United States) Revenue, Net Income and Gross profit
  • Figure 34. Eli Lilly and Company(United States) Revenue: by Geography 2023
  • Figure 35. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Merck & Co. (United States) Revenue: by Geography 2023
  • Figure 37. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 38. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 39. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 40. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 41. Celgene (United States) Revenue, Net Income and Gross profit
  • Figure 42. Celgene (United States) Revenue: by Geography 2023
  • Figure 43. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 44. Novartis (Switzerland) Revenue: by Geography 2023
  • Figure 45. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 46. Amgen (United States) Revenue: by Geography 2023
  • Figure 47. Global Blockbuster Drugs: by Type USD Million (2025-2030)
  • Figure 48. Global Blockbuster Drugs: by Application USD Million (2025-2030)
  • Figure 49. Global Blockbuster Drugs: by Route of Administration USD Million (2025-2030)
  • Figure 50. Global Blockbuster Drugs: by Distribution Channel USD Million (2025-2030)
  • Figure 51. South America Blockbuster Drugs Share (%), by Country
  • Figure 52. Asia Pacific Blockbuster Drugs Share (%), by Country
  • Figure 53. Europe Blockbuster Drugs Share (%), by Country
  • Figure 54. MEA Blockbuster Drugs Share (%), by Country
  • Figure 55. North America Blockbuster Drugs Share (%), by Country
  • Figure 56. Global Blockbuster Drugs: by Type K Tons (2025-2030)
  • Figure 57. Global Blockbuster Drugs: by Application K Tons (2025-2030)
  • Figure 58. Global Blockbuster Drugs: by Route of Administration K Tons (2025-2030)
  • Figure 59. Global Blockbuster Drugs: by Distribution Channel K Tons (2025-2030)
  • Figure 60. South America Blockbuster Drugs Share (%), by Country
  • Figure 61. Asia Pacific Blockbuster Drugs Share (%), by Country
  • Figure 62. Europe Blockbuster Drugs Share (%), by Country
  • Figure 63. MEA Blockbuster Drugs Share (%), by Country
  • Figure 64. North America Blockbuster Drugs Share (%), by Country
  • Figure 65. Global Blockbuster Drugs: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Roche (Switzerland)
  • Bristol-Myers Squibb(United States)
  • Pfizer(United States)
  • Eli Lilly and Company(United States)
  • Merck & Co. (United States)
  • Johnson & Johnson (United States)
  • AstraZeneca (United Kingdom)
  • Celgene (United States)
  • Novartis (Switzerland)
  • Amgen (United States)
Additional players considered in the study are as follows:
Johnson & Johnson (United States) , Bristol Myers Squibb (United States)
Select User Access Type

Key Highlights of Report


Jul 2024 244 Pages 83 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Blockbuster Drugs Market Quantitative research analysis
Global Blockbuster Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Roche (Switzerland), Bristol-Myers Squibb(United States), Pfizer(United States), Eli Lilly and Company(United States), Merck & Co. (United States), Johnson & Johnson (United States), AstraZeneca (United Kingdom), Celgene (United States), Novartis (Switzerland) and Amgen (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"The structural trend of increasing pharmaceuticals spending in richer countries and the rising cost of clinical trials still push pharmaceutical groups to focus on the most profitable therapeutic areas cholesterol, oncology, central nervous system, etc" is seen as one of major influencing trends for Blockbuster Drugs Market during projected period 2023-2030.
The Blockbuster Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Blockbuster Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Glutathione Drugs Comprehensive Study by Type (Tablet, Powder Injection), Application (Hospital, Clinic, Drug Centre, Other), Distribution Channel (Online, Offline), Glutathione (Oxidized Glutathione...
$ 3450
Neurological Disease Treatment Comprehensive Study by Drugs (Antipsychotic, Antiepileptic, Anticholinergic, Analgesics, Hypnotic and Sedative, Antihypertensive, Anticoagulants, Others), Distribution ...
$ 3750
Metabolic Disease Treatment Comprehensive Study by Type (Glycogen Metabolism Disease Drug, Lipid Metabolism Disease Drug, Amino Acid Metabolism Drug), Application (Hospital, Retail Pharmacy), Route o...
$ 3350
Gynecological Cancer Drugs Comprehensive Study by Type (Uterine Cancer, Ovarian Cancer, Vaginal Cancer, Vulvar Cancer, Cervical Cancer), Application (Hospital, Clinic, Other), Physical Examination...
$ 3750
Hyperlipidemia Drugs Comprehensive Study by Drugs (Statins (atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin), Bile-acid-Binding Resins (cholestyramine, ...
$ 3750
Recombinant Human Growth Hormone Comprehensive Study by Application (Growth Hormone (GH) Deficiency, Adult GH Deficiency, Pediatric GH Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Wi...
$ 3750